Evidence map›Paper›PMID 12519608›Full record

SynthesisThe Cochrane database of systematic reviews2002

Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia.

S A Areosa, E V Grimley

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Strategies for dementia prevention: latest evidence and implications.Therapeutic advances in chronic disease · 2017
    Review
  9. Obesity and brain illness: from cognitive and psychological evidences to obesity paradox.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017
    Review
  10. Treatment of Vascular Cognitive Impairment.Current treatment options in neurology · 2015
    Article
  11. Review
  12. Article
  13. Effects of hypertension and diabetes on sentence comprehension in aging.The journals of gerontology. Series B, Psychological sciences and social sciences · 2013
    Article
  14. Vascular cognitive impairment.Current atherosclerosis reports · 2013
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

S A Areosac/ Mauricio Legendre 17, 5-A, Madrid, Spain, 28046. almudenaareosa@hotmail.com
E V Grimley
University of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is increasing interest in preventing cognitive impairment and dementia in later life. Epidemiological evidence shows a relationship between cognitive impairment and Type II diabetes. This association is stronger in patients who have been diagnosed for longer periods of time and in those who are on insulin therapy. There is little information on the short- and long-term influence of type of treatment and level of metabolic control on cognitive function of people with diabetes.

objectivesTo assess the effects of different types and intensities of treatments for Type II diabetes on cognitive function. SEARCH STRATEGY: The Cochrane Control Trials Register, MEDLINE, EMBASE, PsycINFO, SIGLE LILACS and CINAHL as well as a number of ongoing trials databases were searched on 11 June 2002 using appropriate strategies. SELECTION CRITERIA: Randomized controlled trials in which different treatments for Type II diabetes have been compared and in which measures of cognitive function were made at entry and after the treatment. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality. Five trials were identified for possible inclusion but none of them could be included. In one, cognitive function was assessed before and after intensive or conventional diabetic treatment, but the comparison was not double-blind. The three other studies explored the effect of different treatments on QOL but did not include appropriate evaluation of cognitive function. The fifth did not report baseline data on cognitive function in the trial groups. MAIN

resultsNo studies were found to be appropriate for inclusion in meta-analysis. REVIEWER'S

conclusionsThere is no convincing evidence relating type or intensity of diabetic treatment to the prevention or management of cognitive impairment in Type II diabetes. Future research on treatments for diabetes should include standardized assessments of cognitive function as outcome measures.

Indexed as

Cognition DisordersDiabetes Mellitus, Type 2HumansHypoglycemic AgentsMemory DisordersRandomized Controlled Trials as TopicHypoglycemic Agents

Identifiers

PMID12519608
OpenAlexW4211018280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.